Go Deep
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,421 | -3.1 | 1.38 | 0.23 | 264.75 |
| Oct 2026 | 20,627 | -2.9 | 1.30 | 0.23 | 247.81 |
| Oct 2026 | 20,420 | -3.2 | 1.38 | 0.23 | 263.99 |
| Oct 2026 | 20,439 | -3.0 | 1.38 | 0.23 | 261.89 |
| Oct 2026 | 20,287 | -3.2 | 1.44 | 0.23 | 274.02 |
| Oct 2026 | 19,958 | -3.5 | 1.57 | 0.23 | 299.62 |
| Oct 2026 | 19,946 | -3.5 | 1.58 | 0.23 | 299.83 |
| Oct 2026 | 19,934 | -3.5 | 1.58 | 0.23 | 300.16 |
C4 Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 6,641,000.0 | 6,152,000.0 | 11,016,000.0 | 11,230,000.0 |
| Net Profit | -23,635,000.0 | -25,129,000.0 | -20,486,000.0 | -32,166,000.0 |
| EPS | -0.2 | -0.2 | -0.2 | -0.4 |
C4 Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 35,947,000.0 | 35,584,000.0 | 20,756,000.0 | 31,096,000.0 | — |
| Net Profit | -104,994,000.0 | -105,316,000.0 | -132,493,000.0 | -128,175,000.0 | — |
| EPS | -1.3 | -1.5 | -2.7 | -2.6 | — |
C4 Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 359,075,000.0 | 349,602,000.0 | 376,451,000.0 | 430,840,000.0 | — |
| Total Liabilities | 102,488,000.0 | 133,616,000.0 | 130,337,000.0 | 141,606,000.0 | — |
| Total Equity | 256,587,000.0 | 215,986,000.0 | 246,114,000.0 | 289,234,000.0 | — |
Owes vs Owns
C4 Therapeutics, Inc. owed $0.31 for every $1 it owned in Jun 2026, down from $0.33 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.31× | 0.29× | 0.38× | 0.35× | 0.33× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
C4 Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 69.2%Receivables 0.7%Fixed assets (tangible) 12.6%Long-term investments 13.5%Other assets 4.0%
How it's funded — Dec 2025
Short-term debt 1.8%Long-term debt 14.9%Other liabilities 11.6%Shareholders' equity 71.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 248.5 | 244.9 | 253.7 | 276.2 |
| Receivables | 2.4 | 3.1 | 11.8 | 1.5 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 45.3 | 63.4 | 71.1 | 77.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 48.6 | 22.4 | 28.0 | 61.0 |
| Other assets | 14.3 | 15.9 | 11.9 | 14.7 |
| Liabilities & equity | ||||
| Short-term debt | 6.4 | 5.8 | 5.2 | 2.3 |
| Long-term debt | 53.6 | 60.0 | 65.8 | 9.2 |
| Payables | 0.9 | 1.3 | 1.4 | 1.2 |
| Other liabilities | 41.6 | 66.5 | 57.9 | 129.0 |
| Shareholders' equity | 256.6 | 216.0 | 246.1 | 289.2 |
| Net tangible assets | 256.6 | 216.0 | 246.1 | 289.2 |
C4 Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -98,694,000.0 | -65,157,000.0 | -106,838,000.0 | -105,939,000.0 | — |
| Investing Activities | -8,601,000.0 | -51,270,000.0 | 158,349,000.0 | 58,422,000.0 | — |
| Financing Activities | 126,399,000.0 | 45,336,000.0 | 45,489,000.0 | 1,147,000.0 | — |